CD44 and neoplasm: LIFR silencing markedly impaired tumor formation and decreased CSCs frequency in vivo, accompanied by diminished SOX2, CD44 and ALDH1A1 expression in samples (Figure 4I–K; Figure S18, Supporting Information).